Senores Pharmaceuticals IPO GMP History
Senores Pharmaceuticals IPO has been listed on December 30, 2024 at a listing price of ₹600, against the issue price of ₹391 — a gain of ₹209 (+53.45%). The GMP peaked at ₹270 on 27 December 2024 and reached a low of ₹120 on 18 December 2024. The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Senores Pharmaceuticals IPO raised ₹582.11 Cr. through its IPO at a price band of ₹372 to ₹391 per share, with a lot size of 38 shares. The IPO was open for subscription from 20 Dec 2024 to 24 Dec 2024.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
GMP trend
Grey market premium sampled three times a day (11 AM, 5 PM, 10 PM). Last updated 10 Nov, 11:39 PM IST.
Day-wise GMP
The last reading of each day, newest first. Arrows compare with the previous day.
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| 27 Dec 2024 | ₹ 270 | ▲ | 69% | — | — |
| 26 Dec 2024 | ₹ 230 | — | 59% | — | — |
| 24 Dec 2024 | ₹ 230 | ▲ | 59% | — | — |
| 23 Dec 2024 | ₹ 220 | ▲ | 56% | — | — |
| 22 Dec 2024 | ₹ 190 | ▲ | 49% | — | — |
| 19 Dec 2024 | ₹ 140 | ▲ | 36% | — | — |
| 18 Dec 2024 | ₹ 120 | — | 31% | — | — |
Senores Pharmaceuticals IPO dates
Key dates from opening to listing. Today is 11 November.
- Open 20 Dec 2024
- Close 24 Dec 2024
- Allotment 26 Dec 2024
- Refund/credit 27 Dec 2024
- Listing 30 Dec 2024
Senores Pharmaceuticals IPO actual listing price
How the grey market's final call compared with the listing-day open.
| Issue price | ₹391 |
|---|---|
| GMP-based estimate (pre-listing) | ₹661 (+69.1%) |
| Listing gain / loss | +₹209 per share |
| Listing date | 30 Dec, 2024 |
| Actual listing price | ₹600 (+53.45%) |
Is Senores Pharmaceuticals IPO GMP reliable?
Grey market premium for Senores Pharmaceuticals IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- 01Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- 02Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- 03Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- 04Cross-check before acting: Review the Senores Pharmaceuticals IPO full review for a fundamentals-based assessment before making any grey market trades.
Senores Pharmaceuticals IPO Kostak rate explained
Two ways the grey market trades an IPO application before listing.
The Kostak rate for Senores Pharmaceuticals IPO was not available during the subscription period. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not available for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Senores Pharmaceuticals IPO
Senores Pharmaceuticals Limited was incorporated as Senores Pharmaceuticals Private Limited on 26 December 2017. It is a global research driven pharmaceutical company developing and making generic products in the B2B segment.
It mainly serves regulated markets such as the US, Canada and the United Kingdom across therapy areas and dosage forms, and focuses on speciality and complex niche products.
Its promoters are Swapnil Jatinbhai Shah and Ashokkumar Vijaysinh Barot.
The IPO was Rs 582.11 crore, with Rs 500.00 crore of fresh issue and Rs 82.11 crore of offer for sale by promoters, a promoter group member and another shareholder. Fresh money was planned for a sterile injectable plant, repaying borrowings and working capital.
Frequently asked
What is the GMP of Senores Pharmaceuticals IPO?
The current Grey Market Premium (GMP) of Senores Pharmaceuticals IPO is ₹ 270.
What is the Kostak Price of Senores Pharmaceuticals IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Senores Pharmaceuticals IPO is not available.
What is the Subject to Sauda Price of Senores Pharmaceuticals IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is not available.
What was the actual listing price of Senores Pharmaceuticals IPO?
Senores Pharmaceuticals IPO listed on December 30, 2024 at ₹600, against the issue price of ₹391 — a gain of +53.45%.
How did the GMP of Senores Pharmaceuticals IPO trend before listing?
The GMP of Senores Pharmaceuticals IPO was rising in its final days before listing. The GMP peaked at ₹270 on 27 December 2024. View the day-wise table above for the complete GMP history.
Explore Senores Pharmaceuticals IPO further
The grey market is one signal. Read it alongside the demand, the reviews and the filings before you decide.
It has listed — go back to the fundamentals.
Category-wise demand from QIB, NII and retail investors, updated through the day.
What brokers and analysts are saying about this issue, in one place.
Check with your PAN whether shares were credited to your demat account.
The grey market called it. Now check the fundamentals.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Read the grey market alongside the subscription book and the offer document before you apply.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
